The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients. The finding contrasts with positive results from previous phase II studies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback